SFStefan Fröhling

Stefan Fröhling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefan Fröhling has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Claudia Scholl

    Department of Internal Medicine III, Ulm University, Ulm, Germany

    2 shared publications
  • Ali Nowrouzi

    Department of Translational Oncology, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany

    1 shared publication
  • Britta Koch

    Department of Internal Medicine III, 2Department of Urology, and 3Institute for Neural Information Processing, Ulm University, 89081 Ulm, Germany

    1 shared publication
  • Christopher M. Hoffmann

    Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany

    1 shared publication
  • Claudia Regina Ball

    Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany

    1 shared publication
  • Felicitas Genze

    Department of Internal Medicine III, 2Department of Urology, and 3Institute for Neural Information Processing, Ulm University, 89081 Ulm, Germany

    1 shared publication

Latest Publications

  • Open Access

    134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma

    by Tim Rath, Stefan Fröhling, Claudia Scholl, Priya Chudasama, Hanno Glimm, Christof von Kalle, Ali Nowrouzi, Manfred Schmidt

  • Open Access

    Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

    by Ninel Azoitei, Christopher M. Hoffmann, Jana M. Ellegast, Claudia R. Ball, Kerstin Obermayer, Ulrike Gößele, Britta Koch, Katrin Faber, Felicitas Genze, Mark Schrader, et al.

    Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions of STK33 are not yet available. Here, using a mass spectrometry-based screen for STK33 protein interaction partners, we report that the HSP90/CDC37 chaperone complex binds to and stabilizes STK33 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of STK33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in KRAS mutant cells in an STK33-dependent manner. Furthermore, HSP90 inhibitor treatment impaired sphere formation and viability of primary human colon tumor-initiating cells harboring mutant KRAS. These findings provide mechanistic insight into the activity of HSP90 inhibitors in KRAS mutant cancer cells, indicate that the enhanced requirement for STK33 can be exploited to target mutant KRAS-driven tumors, and identify STK33 depletion through HSP90 inhibition as a biomarker-guided therapeutic strategy with immediate translational potential.